Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Healthcare stocks drag
Thu, 9 Apr 01:30 pm

Indian markets held on to their early gains in the post noon session. The is currently trading with gains of 118 points while NSE-Nifty is up by 42 points. Healthcare sector tanked over 1.5% today, however, other sectoral indices are trading with moderate gains. Banks are highest gainers in today's session. On the other hand, BSE Mid Cap and BSE Small Cap are trading with gains of 0.5% and 0.7%, respectively.

Commodities have extended their losses. Both the gold and silver prices have declined by 0.7%. Gold prices, per 10 grams, have lost about Rs 191 while silver prices, per kilogram, have lost about Rs 300. While the gold prices are trading at Rs 26,600 levels, silver prices are trading at Rs 36,670 levels. Crude oil prices are trading on a flattish tone after falling over 4% owing to US report on crude oil inventory. The Dollar value against the Indian Rupee is flat at the moment.

Power is trading on a flattish note. The highest gainers in the sector are Adani Power and KSK energy. These companies have gained 2.7% and 1.3%, respectively. Shares of Powergrid are trading with moderate profits of about 0.5%. Powergrid Corporation of India has taken the call of allowing the Sri Lankan counterpart - Ceylon Electricity Board to take a call on executing an Rs 30 bn, 500 MW power project. The project involves building an undersea power transmission link between India and Sri Lanka.

The Healthcare sector witnessed a sell off after gaining consecutively for 3 trading days. The sectoral index fell as much as 2% during today's trading session. According to a leading financial daily, the Government of India has given a green signal to proposals for raising capital in the healthcare sector whose total value is Rs 41.87 bn. These proposals are predominantly from Glenmark and Aurobindo Pharma. Both the companies have sought approval to raise capital via foreign players since the regulatory board has given approval for increase in the foreign stake. Glenmark has sought FIIs limit to increase upt o 49% while Aurobindo Pharma has sought to infuse fresh capital of up to 7% of its equity.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Healthcare stocks drag". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.